×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:CDMO

Avid Bioservices Stock Forecast, Price & News

$15.33
+0.07 (+0.46%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$14.84
$15.72
50-Day Range
$11.63
$16.75
52-Week Range
$11.30
$34.51
Volume
476,142 shs
Average Volume
626,925 shs
Market Capitalization
$946.54 million
P/E Ratio
95.82
Dividend Yield
N/A
Price Target
$27.00

Avid Bioservices Stock Forecast (MarketRank)

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
74.0% Upside
$26.67 Price Target
Short Interest
Bearish
10.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.96
Upright™ Environmental Score
News Sentiment
0.36mentions of Avid Bioservices in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$235.43 K Sold Last Quarter
Proj. Earnings Growth
22.22%
From $0.18 to $0.22 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.54 out of 5 stars

Medical Sector

161st out of 1,429 stocks

Pharmaceutical Preparations Industry

56th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive CDMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

Avid Bioservices logo

About Avid Bioservices (NASDAQ:CDMO)

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

CDMO Stock News Headlines

Read How Avid Bioservices Fared In Q4
Avid Bioservices's Earnings Outlook
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDMO
Employees
252
Year Founded
N/A

Company Calendar

Last Earnings
12/07/2021
Today
7/01/2022
Next Earnings (Estimated)
9/14/2022
Fiscal Year End
4/30/2023

Price Target and Rating

Average Stock Price Forecast
$26.67
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+76.1%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
3 Analysts

Profitability

Net Income
$11.21 million
Pretax Margin
12.13%

Debt

Sales & Book Value

Annual Sales
$95.87 million
Cash Flow
$0.25 per share
Book Value
$1.28 per share

Miscellaneous

Free Float
60,824,000
Market Cap
$946.54 million
Optionable
Optionable
Beta
2.31














Avid Bioservices Frequently Asked Questions

Should I buy or sell Avid Bioservices stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avid Bioservices stock.
View analyst ratings for Avid Bioservices
or view top-rated stocks.

What is Avid Bioservices' stock price forecast for 2022?

3 Wall Street research analysts have issued twelve-month price objectives for Avid Bioservices' shares. Their CDMO stock forecasts range from $22.00 to $30.00. On average, they anticipate Avid Bioservices' stock price to reach $26.67 in the next year. This suggests a possible upside of 74.0% from the stock's current price.
View analysts' price targets for Avid Bioservices
or view top-rated stocks among Wall Street analysts.

How has Avid Bioservices' stock price performed in 2022?

Avid Bioservices' stock was trading at $29.18 at the start of the year. Since then, CDMO shares have decreased by 47.5% and is now trading at $15.33.
View the best growth stocks for 2022 here
.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release its next quarterly earnings announcement on Wednesday, September 14th 2022.
View our earnings forecast for Avid Bioservices
.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) posted its earnings results on Tuesday, December, 7th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.04. The biopharmaceutical company had revenue of $26.11 million for the quarter, compared to analysts' expectations of $25 million. Avid Bioservices had a trailing twelve-month return on equity of 27.58% and a net margin of 12.13%. During the same quarter in the previous year, the firm earned $0.01 earnings per share.
View Avid Bioservices' earnings history
.

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Shares of Avid Bioservices reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices issued an update on its FY 2023 earnings guidance on Wednesday, June, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $140.00 million-$145.00 million, compared to the consensus revenue estimate of $146.50 million.

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the following people:
  • Mr. Nicholas Stewart Green B.Sc., MBA, Pres, CEO & Director (Age 57, Pay $1.55M) (LinkedIn Profile)
  • Mr. Daniel R. Hart, Chief Financial Officer (Age 49, Pay $899.28k) (LinkedIn Profile)
  • Mr. Mark R. Ziebell J.D., VP, Gen. Counsel & Corp. Sec. (Age 58, Pay $707.75k) (LinkedIn Profile)
  • Mr. Richard Richieri, Chief Operations Officer (Age 57)
  • Ms. Lorna Larson, Sr. Director of HR
  • Mr. Matthew Kwietniak, Chief Commercial Officer
  • Dr. Shelley P. M. Fussey, VP of Intellectual Property (Age 56)
  • Ms. Tracy L. Kinjerski, VP of Bus. Operations
  • Dr. Harold F. Dvorak, Medical & Scientific Advisor
  • Prof. Alan J. Schroit, Medical & Scientific Advisor

What is Roger Lias' approval rating as Avid Bioservices' CEO?

2 employees have rated Avid Bioservices CEO Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among Avid Bioservices' employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $15.33.

How much money does Avid Bioservices make?

Avid Bioservices (NASDAQ:CDMO) has a market capitalization of $946.54 million and generates $95.87 million in revenue each year. The biopharmaceutical company earns $11.21 million in net income (profit) each year or $0.159990 on an earnings per share basis.

How many employees does Avid Bioservices have?

Avid Bioservices employs 252 workers across the globe.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The official website for Avid Bioservices is www.avidbio.com. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at [email protected], or via fax at 714-838-5817.

This page (NASDAQ:CDMO) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.